Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 131 to 140 of 298 total matches.

Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022  (Issue 1652)
of drugs metabolized by these isozymes, including oral contraceptives. Use of mavacamten ...
The FDA has approved mavacamten (Camzyos – MyoKardia/BMS), a modulator of cardiac myosin, to improve functional capacity and symptoms in adults with New York Heart Association (NYHA) class II or III obstructive hypertrophic cardiomyopathy (HCM) who have a baseline left ventricular ejection fraction (LVEF) ≥55%. Mavacamten is the first drug in its class to become available in the US.
Med Lett Drugs Ther. 2022 Jun 13;64(1652):89-91 |  Show IntroductionHide Introduction

Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
contraception does not qualify for treatment with the drug. VULVOVAGINAL CANDIDIASIS — Vulvovaginal ...
The FDA has approved oteseconazole (Vivjoa – Mycovia), a new oral azole antifungal, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC. Oteseconazole is the first drug to be approved in the US specifically for treatment of RVVC.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):124-6 |  Show IntroductionHide Introduction

Drugs that Cause Photosensitivity

   
The Medical Letter on Drugs and Therapeutics • Apr 14, 1995  (Issue 946)
(Atromid-S, and others) Contraceptives, oral Desoximetasone (Topicort, and others) Disopyramide (Norpace ...
As the weather becomes warmer, physicians may see more photosensitivity reactions due to systemic or topical drugs, perfumes, cosmetics or sunscreens. Even brief exposure to sunlight in warm or cold weather can cause intense cutaneous reactions in patients with drug-induced photosensitivity, and some patients may continue to be sensitive to sunlight long after stopping use of the offending agent.
Med Lett Drugs Ther. 1995 Apr 14;37(946):35-6 |  Show IntroductionHide Introduction

Vandetanib (Caprelsa) for Medullary Thyroid Cancer

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2012  (Issue 1381)
(positive evidence of risk) for use during pregnancy. Women of child-bearing age should use contraception ...
The FDA recently approved vandetanib [van det´ a nib] (Caprelsa – AstraZeneca) for oral treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Vandetanib is the first drug approved in the US for medullary thyroid cancer.
Med Lett Drugs Ther. 2012 Jan 9;54(1381):3-4 |  Show IntroductionHide Introduction

Ado-Trastuzumab Emtansine (Kadcyla) for HER2-Positive Metastatic Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2013  (Issue 1425)
of risk) for use during pregnancy. Women of child-bearing age should use effective contraception during ...
Ado-trastuzumab emtansine (Kadcyla – Genentech), a human epidermal growth factor receptor 2 (HER2)-targeted antibody and microtubule inhibitor conjugate, has been approved by the FDA for intravenous (IV) treatment of HER2-positive metastatic breast cancer in patients previously treated with trastuzumab (Herceptin) and a taxane. The prefix was added to the new conjugate’s name at the request of the FDA to distinguish it from trastuzumab.
Med Lett Drugs Ther. 2013 Sep 16;55(1425):75-6 |  Show IntroductionHide Introduction

Olaratumab (Lartruvo) for Soft-Tissue Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017  (Issue 1527)
should use contraception during treatment and for 3 months after the last dose. Whether olaratumab ...
Olaratumab (Lartruvo – Lilly), a platelet-derived growth factor receptor alpha (PDGFR-α) blocking monoclonal antibody, has received accelerated approval from the FDA for use in combination with the anthracycline doxorubicin for first-line treatment of adults with soft-tissue sarcoma histologic subtypes considered susceptible to anthracyclines. Approval is limited to locally advanced or metastatic soft-tissue sarcomas that are not amenable to curative radiotherapy or surgery, and is contingent on verification of clinical benefit in a confirmatory phase 3 trial.
Med Lett Drugs Ther. 2017 Aug 14;59(1527):e138-9 |  Show IntroductionHide Introduction

Lutetium Lu 177 Dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 10, 2018  (Issue 1555)
potential and their male partners should use effective contraception during treatment and for 7 months ...
The FDA has approved lutetium Lu 177 dotatate (Lutathera – Advanced Accelerator Applications), a radiolabeled somatostatin analog, for treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEPNETs) in adults.
Med Lett Drugs Ther. 2018 Sep 10;60(1555):e152-3 |  Show IntroductionHide Introduction

Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
with female partners of reproductive potential should use effective contraception during treatment ...
The oral kinase inhibitor alpelisib (Vijoice – Novartis) has been approved by the FDA for treatment of patients ≥2 years old with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic treatment. Alpelisib is the first drug to be approved in the US for this indication. It was also approved in 2019 as Piqray for use in combination with fulvestrant for treatment of certain types of breast cancer.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e186-7 |  Show IntroductionHide Introduction

In Brief: Zanubrutinib (Brukinsa) for CLL or SLL (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
contraceptive method while taking the drug and for 1 week after the last dose. No data are available ...
The Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa), which was previously approved by the FDA for treatment of mantle cell lymphoma, Waldenström's macroglobulinemia, and relapsed or refractory marginal zone lymphoma, has now been approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in adults. The BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence) were approved earlier for treatment of CLL and SLL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e33-4   doi:10.58347/tml.2023.1670e |  Show IntroductionHide Introduction

In Brief: A Second Indication for Tucatinib (Tukysa) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023  (Issue 1670)
at the recommended dose. Women of reproductive potential and their male partners should use effective contraception ...
The oral kinase inhibitor tucatinib (Tukysa – Seagen) has received accelerated approval from the FDA for use in combination with trastuzumab (Herceptin) for treatment of adults with RAS wild-type human epidermal growth factor receptor 2 (HER2)-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy regimens. Tucatinib was approved in 2020 for use in combination with trastuzumab and capecitabine (Xeloda, and generics) for treatment of adults with advanced unresectable or...
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e37-8   doi:10.58347/tml.2023.1670g |  Show IntroductionHide Introduction